News

2010 Lecture: US Health Care Reform

27 May 2010

OHE’s 2010 Annual Lecture features Dr Alan Garber on the implications of the American health care reform law. Register to join us in London on 22…

The Impact of Biosimilars on Markets

24 May 2010

The availability of biosimilars — ‘copies’ of biologics — is very recent and limited so far to only a few products. Projecting the impact on markets…

HTAinSite

HTAinSite: The NICE Decision Database

18 May 2010

HTAinSite is a unique resource that enables subscribers to quickly find relevant information on NICE technology appraisal (TA) decisions and the evidence used to support them.…

Workshop on HTA and Regulatory Review

13 May 2010

Tensions between broad access to new medical technologies and efforts to contain health care costs are perennial. In recent years, this has become evident in the…

Cracks through the ice on a melting glacier in Alaska

Risk Sharing & Patient Access Schemes Workshop

10 May 2010

On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market…

Jorge Mestre-Ferrandiz

OHE’s Mestre-Ferrandiz has new appointment

4 May 2010

OHE is delighted to announce that Dr Jorge Mestre-Ferrandiz has been appointed an Honorary Visiting Lecturer in the Department of Economics at City University London.

Cracks through the ice on a melting glacier in Alaska

Time Trade Off and Valuing Quality of Life

28 April 2010

In an article in Health Economics, Prof Devlin and her co-authors demonstrate the promise of using Lead Time TTO to value health ‘state worse than death’.…

Tony Atkinson

Measuring Health Output, Productivity and Equity

20 April 2010

Why, whether and how to measure health outputs, productivity and equity in the UK was the focus of the OHE’s 15th Annual Lecture, given by Prof…

Cracks through the ice on a melting glacier in Alaska

OHE Lunchtime Seminar on Pricing

15 April 2010

The 13 April OHE Lunchtime Seminar with Prof William Comanor was attended by about 40 people, hailing from academia, the pharmaceutical and biotechnology industries, consultancies, physicians’…